Bivalirudin0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Bivalirudin — research data
Regulatory statusFDA-approved (Angiomax)
NCAA D1Not listed
Overview
About Bivalirudin
Mechanism of action
Direct thrombin inhibitor hirudin analog; binds both free and clot-bound thrombin reversibly
Safety profile
Bleeding, back pain, hypotension, bradycardia · Extensive clinical use; predictable pharmacokinetics; manageable bleeding risk
Related pages